Online inquiry

IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ382MR)

This product GTTS-WQ382MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TYRP1 gene. The antibody can be applied in Malignant melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000550.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7306
UniProt ID P17643
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ382MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10457MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ14937MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1878MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ3786MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ9676MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ9622MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ4282MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ7863MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW